Redeye updates on Strax following Q4 results, with weaker than expected topline and additional inventory write-offs. The company's outlook remains uncertain due to persistent challenges in the underlying market, leading to adjustments in our estimates and a downward revision of the valuation range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Strax - Soft topline and more write-downs

© Modular Finance, source Nordic Press Releases